Based treatment algorithm for essencial hypertension with olmesartan medoxomil.
BACKGROUND
The national and international guidelines emphasize the importance of the effective treatment of arterial hypertension. Nevertheless, low levels of control are observed, as well as low attainment of the recommended goals, indicating that it is important to plan and implement better treatment strategies.


OBJECTIVE
To evaluate the efficacy of a based treatment algorithm with olmesartan medoxomil.


METHODS
This is an open, national, multicentric and prospective study of 144 patients with primary arterial hypertension, stages 1 and 2, naïve to treatment or after a 2-to-3 week washout period for those in whom treatment was ineffective. The use of olmesartan medoxomil was assessed in a treatment algorithm divided into 4 phases: (i) monotherapy (20 mg), (ii-iii) associated to à hydrochlorothiazide (20/12.5 mg and 40/25 mg) and (iv) addition of amlodipine besylate (40/25 mg + 5 mg).


RESULTS
At the end of the phased-treatment, 86% of the study subjects attained the goal of BP < 130/85 mmHg. Maximum reductions in SAP and DAP were -44.4 mmHg and -20.0 mmHg, respectively. The rate of systolic responders (SAP >or= 20 mmHg) and of diastolic responders (DAP >or= 10 mmHg) was 87.5% and 92.4%, respectively.


CONCLUSIONS
The study was based on a treatment regimen that was similar to the therapeutic approach in daily clinical practice and showed that the use of olmesartan medoxomil in monotherapy or in association with hydrochlorothiazide and amlodipine was effective in the attainment of the recommended goals for hypertension stage 1 and 2 hypertensive individuals.
Gomes
Marco Antônio Mota
MA
Faculdade de Medicina, Universidade Estadual de Ciências da Saúde de Alagoas, Maceió, AL, Brasil. mota-gomes@uol.com.br
Feitosa
Audes Diógenes de Magalhães
AD
Oigman
Wille
W
Ribeiro
José Márcio
JM
Moriguchi
Emílio Hideyuki
EH
Saraiva
José Francisco Kerr
JF
Précoma
Dalton Bertolim
DB
Ribeiro
Artur Beltrame
AB
Amodeo
Celso
C
Brandão
Andréa Araujo
AA
D000328:Adult; D000368:Aged; D000465:Algorithms; D017311:Amlodipine / Q000009:adverse effects / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000009:adverse effects / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000068557:Olmesartan Medoxomil; D011446:Prospective Studies; D012016:Reference Values; D012720:Severity of Illness Index; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D007093:Imidazoles; D013777:Tetrazoles; D006852:Hydrochlorothiazide; D017311:Amlodipine; D000068557:Olmesartan Medoxomil